X4 PHARMACEUTICALS, INC Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period
X4 PHARMACEUTICALS, INC (XFOR) reported Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period of 4.69 million shares for the 3-month period ending 2023-03-31, per its 10-Q filed 2023-05-04.
Discontinued › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod · last filed 2023-05-04
- X4 PHARMACEUTICALS, INC share-based compensation arrangement by share-based payment award, equity instruments other than options, grants in period for the quarter ending 2023-03-31 was 4.69M shares, a 277.76% increase year-over-year.
- X4 PHARMACEUTICALS, INC share-based compensation arrangement by share-based payment award, equity instruments other than options, grants in period for the quarter ending 2022-09-30 was 0.00 shares, a 100.00% decline year-over-year.
- X4 PHARMACEUTICALS, INC share-based compensation arrangement by share-based payment award, equity instruments other than options, grants in period for the quarter ending 2022-06-30 was 46.67K shares, a 1173.02% increase year-over-year.
- X4 PHARMACEUTICALS, INC share-based compensation arrangement by share-based payment award, equity instruments other than options, grants in period for the quarter ending 2022-03-31 was 1.24M shares, a 110.35% increase year-over-year.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period 9 month |
|---|---|---|---|
| 2023-03-31 | 4.69M shares 10-Q · filed 2023-05-04 | ||
| 2022-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | 46.67K shares derived: sum of 2 quarters · filed 2022-11-03 | 1.29M shares 10-Q · filed 2022-11-03 |
| 2022-06-30 | 46.67K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | 1.29M shares 10-Q · filed 2022-08-04 | |
| 2022-03-31 | 1.24M shares 10-Q · filed 2022-05-12 | ||
| 2021-09-30 | 55.00K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | 58.67K shares derived: sum of 2 quarters · filed 2021-11-04 | 649.48K shares 10-Q · filed 2021-11-04 |
| 2021-06-30 | 3.67K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-03 | 594.48K shares 10-Q · filed 2021-08-03 | |
| 2021-03-31 | 590.81K shares 10-Q · filed 2021-05-06 | ||
| 2020-09-30 | 23.10K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | 681.08K shares 10-Q · filed 2020-11-05 | |
| 2020-06-30 | 657.98K shares 10-Q · filed 2020-08-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |